FY2025 EPS Estimate for Axsome Therapeutics Cut by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of ($4.15) per share for the year, down from their prior forecast of ($2.88). Cantor Fitzgerald currently has a “Overweight” rating and a $153.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

Several other research firms have also commented on AXSM. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Royal Bank of Canada increased their price target on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 target price for the company. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday. Finally, Needham & Company LLC increased their target price on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $155.47.

Axsome Therapeutics Price Performance

AXSM stock opened at $129.15 on Friday. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $134.18. The company has a current ratio of 2.11, a quick ratio of 2.37 and a debt-to-equity ratio of 3.22. The company has a 50-day moving average price of $100.34 and a 200 day moving average price of $94.46. The stock has a market cap of $6.30 billion, a PE ratio of -21.56 and a beta of 1.05.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 22.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raiffeisen Bank International AG purchased a new position in Axsome Therapeutics in the 4th quarter valued at $51,000. Assetmark Inc. purchased a new position in Axsome Therapeutics in the 4th quarter valued at $52,000. R Squared Ltd purchased a new position in Axsome Therapeutics in the 4th quarter valued at $64,000. Aquatic Capital Management LLC purchased a new position in Axsome Therapeutics in the 4th quarter valued at $76,000. Finally, GF Fund Management CO. LTD. purchased a new position in Axsome Therapeutics in the 4th quarter valued at $86,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.